ホーム › 乳がん › ユタ › Salt Lake City
Salt Lake City、UTにおける乳がんの臨床試験
Salt Lake Cityとその周辺地域（約30マイル以内）の拠点で、乳がんに関する27件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
被験者募集中第3相
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
被験者募集中第3相
- Clinical Trial Site, Salt Lake City
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
被験者募集中第3相
- Utah Cancer Specialists, Salt Lake City
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
被験者募集中第2相
- Huntsman Cancer Institute, Salt Lake City
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
被験者募集中第3相
- Utah Cancer Specialists, Salt Lake City
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
被験者募集中第1/2相
- University of Utah Huntsman Cancer Institute, Salt Lake City
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
被験者募集中第3相
- Huntsman Cancer Hospital at the University of Utah, Salt Lake City
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
被験者募集中第3相
- University of Utah Sugarhouse Health Center, Salt Lake City
- Huntsman Cancer Institute/University of Utah, Salt Lake City
- Farmington Health Center, Farmington · 15マイル先
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
被験者募集中第1相
- Intermountain/LDS Hospital Ph 1 Research Program, Salt Lake City
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
被験者募集中第2相
- Huntsman Cancer Institute at University of Utah, Salt Lake City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
被験者募集中第3相
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
被験者募集中第3相
- University of Utah - Huntsman Cancer Institute, Salt Lake City
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
被験者募集中第1/2相
- Huntsman Cancer Institute, Salt Lake City
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
被験者募集中第2相
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
被験者募集中第3相
- Huntsman Cancer Institute, Salt Lake City
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
被験者募集中
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
被験者募集中第3相
- Utah Cancer Specialists-Salt Lake City, Salt Lake City
- LDS Hospital, Salt Lake City
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
被験者募集中第1/2相
- START Center for Cancer Care - Mountain Region, Salt Lake City
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
被験者募集中早期第1相
- Huntsman Cancer Institute at University of Utah, Salt Lake City
Improving Care for Rural Patients With Solid Tumors
被験者募集中
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
被験者募集中第2相
- Huntsman Cancer Institute/University of Utah, Salt Lake City
SAVE Trial: SAfe Opioid Use Video Education
被験者募集中
- University of Utah Huntsman Cancer Institute, Salt Lake City
Enhancing Mammography Programs for Outreach, Wellness, Education, and Resources (EMPOWER) in Underserved Populations Study
被験者募集中健康なボランティア歓迎
- Huntsman Cancer Institute/ University of Utah, Salt Lake City
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Salt Lake City
Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies
被験者募集中第3相
- Huntsman Cancer Institute at University of Utah, Salt Lake City
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
被験者募集中第1相
- University of Utah- Huntsman Cancer Center, Salt Lake City
Community Services Navigation to Advance Health Equity in Breast Cancer Screening
被験者募集中
- University of Utah Health Hospitals/Huntsman Cancer Institute Population Sciences, Salt Lake City
他の都市における乳がんの試験
- New York City, NY136件の研究
- Houston, TX126件の研究
- Boston, MA112件の研究
- Nashville, TN81件の研究
- Los Angeles, CA73件の研究
- Edison, NJ68件の研究
- St. Louis, MO64件の研究
- Queens, NY64件の研究
- Durham, NC64件の研究
- Chicago, IL59件の研究
- Philadelphia, PA56件の研究
- Dallas, TX55件の研究
Salt Lake Cityにおける他の研究
- 非小細胞肺癌31件の研究
- がん（全種類）27件の研究
- 大腸癌22件の研究
- 肺がん21件の研究
- 悪性黒色腫21件の研究
- 多発性骨髄腫21件の研究
- 転移性癌20件の研究
- 卵巣がん19件の研究
- 肥満症18件の研究
- 急性骨髄性白血病17件の研究
- 心不全17件の研究
- 前立腺がん15件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。